Company Overview and News
LONDON, UK / ACCESSWIRE / November 16, 2017 / Atossa Genetics (NASDAQ: ATOS) reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high mammographic breast density (MBD), which is associated with increased breast cancer risk. The firm is also developing oral endoxifen for patients refractory to tamoxifen, and its intraductal microcatheter (IDMC), combined with established cancer drug fulvestrant. (195-3)
* Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics Inc, as of Oct 26 - SEC filing Source text: (bit.ly/2iIbgjU) Further company coverage: (195-1)
* Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing Source text: (bit.ly/2z0yYCe) Further company coverage: (195-4)
Atossa Genetics Inc (NASDAQ:ATOS) has 14 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,241,770 shares. Largest shareholders include Empery Asset Management, LP, Renaissance Technologies LLC, Sabby Management, Llc, Hudson Bay Capital Management LP, and Vanguard Group Inc. (195-5)
SAN FRANCISCO, CA / ACCESSWIRE / October 31, 2017 / Vista Partners ("Vista") has published October's FREE Macroeconomic & Investment Monthly Newsletter, "Economy Still Growing Strong?" (265-0)
SAN FRANCISCO, CA / ACCESSWIRE / September 27, 2017 / Vista Partners ("Vista") has published September's FREE Macroeconomic & Investment Monthly Newsletter, "Keeps on Keepin' On." (216-1)
NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive report with no obligation on Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. (210-3)
* Atossa Genetics Inc says expects to announce results from oral arm of Phase 1 study in next 30-60 days (2-1)
Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Biotechnology, Cloud Services, Energy, Fintech, Healthcare Insurance, SaaS, Technology, and More
SEATTLE, WA--(Marketwired - Jun 30, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that holders of approximately 51% of the warrants issued in the public offering that closed on April 3, 2017 have exercised their warrants on a cashless basis. The Company offered all holders of the warrants the opportunity on or before 8 a. (0-2)
* Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults (0-1)
* Atossa Genetics - On June 29, offered to modify rights of holders of warrants issued in public offering company completed on April 3, 2017 - SEC Filing (0-1)
* Southwest Airlines Co - senior vice president and chief information officer Randy Sloan is leaving company in mid-July
RIO DE JANEIRO, June 30 Exploration and production, refining and logistics activities at Brazilian state-controlled oil company Petróleo Brasileiro are normal on Friday amid a nationwide strike, executives said.
SEATTLE, WA--(Marketwired - Jun 26, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a positive interim safety assessment of the first cohort receiving proprietary oral Endoxifen in its Phase 1 dose escalation study. Endoxifen is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high-risk patients.
Stock Research Report
Atossa Genetics is a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company currently have three programs underway: two using its proprietary endoxifen (oral and topical formulations) and the other using its patented microcatheter technology. The company's proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. The company's patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.
Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years to both treat and prevent breast cancer. Additional research has shown that it is the metabolites of tamoxifen, o...
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton